Copula-based survival regression models, which consist of a copula function and marginal distribution (i.e., marginal survival function), have been widely used for analyzing clustered multivariate survival data. Archimedean copula functions are useful for modeling such dependence. For the likelihood inference, one-stage and two-stage estimation methods have been usually used. The two-stage procedure can give inefficient estimation results because of separate estimation of the marginal and copula's dependence parameters. The more efficient one-stage procedure has been mainly developed under a restrictive parametric assumption of marginal distribution due to complexity of the full likelihood with unknown marginal baseline hazard functions. In this paper, we propose a flexible parametric Archimedean copula modeling approach using a one-stage likelihood procedure. In order to reduce the complexity of the full likelihood, the unknown marginal baseline hazards are modeled based on a cubic M-spline basis function that does not require a specific parametric form. Simulation results demonstrate that the proposed one-stage estimation method gives a consistent estimator and also provides more efficient results over existing one- and two-stage methods. The new method is illustrated with three clinical data sets. The Appendix provides an R function so that the proposed method becomes directly accessible to interested readers.

Download full-text PDF

Source
http://dx.doi.org/10.1002/pst.2153DOI Listing

Publication Analysis

Top Keywords

flexible parametric
8
copula modeling
8
survival data
8
marginal distribution
8
archimedean copula
8
complexity full
8
full likelihood
8
likelihood unknown
8
unknown marginal
8
marginal baseline
8

Similar Publications

Predictive value of metabolic syndrome for prostate cancer risk is not clear. We aimed to assess the association between metabolic syndrome and its components with prostate cancer incidence. The primary outcome was prostate cancer incidence, i.

View Article and Find Full Text PDF

Anti-ambipolar transistors (AAT) are considered as a breakthrough technology in the field of electronics and optoelectronics, which is not only widely used in diverse logic circuits, but also crucial for the realization of high-performance photodetectors. The anti-ambipolar characteristics arising from the gate-tunable energy band structure can produce high-performance photodetection at different gate voltages. As a result, this places higher demands on the parametric driving range (ΔVg) and peak-to-valley ratio (PVR) of the AAT.

View Article and Find Full Text PDF

Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia around the world with an increased risk of a broad spectrum of adverse comorbidities and death. Whether cardiovascular health (CVH) is associated with AF development remains unclear.

Methods: 238,420 participants without cardiovascular disease at baseline were selected from the UK Biobank study cohort from 2006 to 2010.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the long-term effects of immunotherapy (IO) for patients with metastatic nonsmall cell lung cancer (mNSCLC), using data from over 10,000 patients.
  • The research compared IO to standard treatments, highlighting that IO offers a modest survival benefit, with an average increase of about 3.2 months for first-line therapy and 2.7 months for second-line therapy.
  • While IO shows potential to extend overall survival and delay the time to next treatment, the long-term effects are still uncertain compared to clinical trial outcomes.
View Article and Find Full Text PDF

Background: The current management of psoriasis does not differentiate between young and old patients in selecting the safest and/or most effective biologic.

Objectives: To explore the effect of age at treatment initiation in response to biologics in patients with moderate-to-severe psoriasis in the UK and Eire.

Methods: Data from patients registering to the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) from 2007-2024 on first course of Tumour Necrosis Factor (TNF), interleukin (IL) 12/13, IL-17 and IL-23 inhibitors (i) with at least 6 months' follow-up were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!